JP7846628B2 - バーコード化可能な交換可能ペプチド－ｍｈｃ多量体ライブラリー - Google Patents

バーコード化可能な交換可能ペプチド－ｍｈｃ多量体ライブラリー

Info

Publication number
JP7846628B2
JP7846628B2 JP2022559619A JP2022559619A JP7846628B2 JP 7846628 B2 JP7846628 B2 JP 7846628B2 JP 2022559619 A JP2022559619 A JP 2022559619A JP 2022559619 A JP2022559619 A JP 2022559619A JP 7846628 B2 JP7846628 B2 JP 7846628B2
Authority
JP
Japan
Prior art keywords
peptide
mhc
mhci
monomer
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520412A (ja
JP2023520412A5 (https=
Inventor
オハッド ヨーセフソン，
トーマス マリア，
アンドリュー ハメル，
ジョアナ スウェイン，
ベンジャミン ロスコー，
モハマド ラシディアン，
Original Assignee
レパトワー イミューン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レパトワー イミューン メディシンズ， インコーポレイテッド filed Critical レパトワー イミューン メディシンズ， インコーポレイテッド
Publication of JP2023520412A publication Critical patent/JP2023520412A/ja
Publication of JP2023520412A5 publication Critical patent/JP2023520412A5/ja
Application granted granted Critical
Publication of JP7846628B2 publication Critical patent/JP7846628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/04—Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022559619A 2020-03-31 2021-03-31 バーコード化可能な交換可能ペプチド－ｍｈｃ多量体ライブラリー Active JP7846628B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003177P 2020-03-31 2020-03-31
US63/003,177 2020-03-31
PCT/US2021/025167 WO2021202727A2 (en) 2020-03-31 2021-03-31 Barcodable exchangeable peptide-mhc multimer libraries

Publications (3)

Publication Number Publication Date
JP2023520412A JP2023520412A (ja) 2023-05-17
JP2023520412A5 JP2023520412A5 (https=) 2024-04-11
JP7846628B2 true JP7846628B2 (ja) 2026-04-15

Family

ID=75660333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559619A Active JP7846628B2 (ja) 2020-03-31 2021-03-31 バーコード化可能な交換可能ペプチド－ｍｈｃ多量体ライブラリー

Country Status (8)

Country Link
US (1) US20230287394A1 (https=)
EP (1) EP4126923A2 (https=)
JP (1) JP7846628B2 (https=)
CN (1) CN115776987A (https=)
AU (1) AU2021248941A1 (https=)
CA (1) CA3176448A1 (https=)
IL (1) IL296789A (https=)
WO (1) WO2021202727A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114644706B (zh) * 2022-02-16 2024-04-09 国家纳米科学中心 基于DNA纳米技术的pMHC多聚体制备方法及其应用
AU2023314797A1 (en) 2022-07-29 2024-12-12 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
JP2017518375A (ja) 2014-06-06 2017-07-06 ヘアレウ ホスピタル Ｍｈｃ多量体のバーコード標識による抗原認識の判定

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
AU3220593A (en) 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
DE10247014A1 (de) * 2002-10-09 2004-04-22 Erfle, Volker, Prof. Priv.-Doz. Dr. MHC-Multimere
GB0226227D0 (en) * 2002-11-09 2002-12-18 Avidex Ltd Receptors
WO2005047902A1 (en) 2003-11-03 2005-05-26 Beckman Coulter, Inc. Solution-based methods for detecting mhc-binding peptides
GB2422834B8 (en) * 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
WO2006136763A1 (en) * 2005-06-20 2006-12-28 Medigene Limited Synthetic ligands of peptide-mhc complexes, or cd1-antigen complexes
GB2430256B (en) 2005-09-19 2008-06-25 Proimmune Ltd A method of screening MHC molecules
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
EP2558491B1 (en) 2010-04-13 2018-07-04 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
CN102296807B (zh) 2011-06-27 2013-06-05 中国葛洲坝集团股份有限公司 管、槽圆弧形混凝土底板轻便滑模
JP6364352B2 (ja) * 2012-01-06 2018-07-25 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
EP2952520A1 (en) * 2014-06-06 2015-12-09 Stichting Sanquin Bloedvoorziening Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides.
WO2015200541A1 (en) 2014-06-24 2015-12-30 Bio-Rad Laboratories, Inc. Digital pcr barcoding
SG11202007686VA (en) * 2018-02-12 2020-09-29 10X Genomics Inc Methods characterizing multiple analytes from individual cells or cell populations
WO2019238939A1 (en) * 2018-06-15 2019-12-19 F. Hoffmann-La Roche Ag A system for identification of antigens recognized by t cell receptors expressed on tumor infiltrating lymphocytes
US20220073908A1 (en) * 2019-01-04 2022-03-10 Repertoire Immune Medicines, Inc. Methods of producing high diversity peptide libraries and promoting protein folding

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
JP2017518375A (ja) 2014-06-06 2017-07-06 ヘアレウ ホスピタル Ｍｈｃ多量体のバーコード標識による抗原認識の判定

Also Published As

Publication number Publication date
IL296789A (en) 2022-11-01
EP4126923A2 (en) 2023-02-08
WO2021202727A2 (en) 2021-10-07
JP2023520412A (ja) 2023-05-17
CA3176448A1 (en) 2021-10-07
US20230287394A1 (en) 2023-09-14
AU2021248941A1 (en) 2022-11-17
CN115776987A (zh) 2023-03-10
WO2021202727A3 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US11668705B2 (en) General detection and isolation of specific cells by binding of labeled molecules
JP7846628B2 (ja) バーコード化可能な交換可能ペプチド－ｍｈｃ多量体ライブラリー
US20230265157A1 (en) Mhc multimer expression constructs and uses thereof
JP7540948B2 (ja) ペプチド－ｍｈｃ ｃｏｍｐａｃｔ
JP2022520230A (ja) 抗原特異的ｔ細胞の同定のための組成物と方法
US20220033460A1 (en) Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
TR201811128T4 (tr) Bir hedef hücrenin tersinir şekilde boyama yöntemi.
US11129872B2 (en) Methods of making and using soluble MHC molecules
US20220090297A1 (en) Peptide libraries and methods of use thereof
WO2022026921A1 (en) Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
Vyasamneni et al. A universal MHCII technology platform to characterize antigen-specific CD4+ T cells
WO2022087154A1 (en) Mhc class ii peptide multimers and uses thereof
US20240076356A1 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
JP2024534825A (ja) 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
HK40095794A (en) General detection and isolation of specific cells by binding of labeled molecules
CN118355277A (zh) 评定mhc-肽-tcr相互作用和动力学的细胞测定和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403

R150 Certificate of patent or registration of utility model

Ref document number: 7846628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150